Business context and reporting period
This is Sevion Therapeutics, Inc.’s unaudited Form 10-Q for the three months ended September 30, 2017 (its fiscal first quarter), not a report filed under the Eloxx Pharmaceuticals name. Sevion was a development-stage biotechnology company pursuing antibody therapeutics. A proposed merger with Eloxx Pharmaceuticals Ltd. was pending; the filing describes Eloxx becoming a Sevion subsidiary and Sevion changing its name to Eloxx Pharmaceuticals, Inc. if the transaction closed.
Financial results and position
| Metric | Quarter ended September 30, 2017 | Comparable 2016 period / prior balance date |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $627,449 | $2,210,532 |
| Net loss | $1,266,978 | $933,577 |
| Net loss applicable to common shares | $1,381,246; $0.03 per share | $943,079; $0.05 per share |
| Cash used in operating activities | $575,324 | $573,744 |
| Cash and cash equivalents | $957,874 at September 30, 2017 | $33,198 at June 30, 2017 |
| Working capital | Deficit of $37,833 | — |
| Total liabilities | $3,276,289 | $4,973,994 at June 30, 2017 |
| Accumulated deficit | $123,205,572 | $121,824,326 at June 30, 2017 |
The company had no revenue, so gross margin and profitability margins are not meaningful. Research and development expense was $135,639, down 51.4% year over year; general and administrative expense was $491,810, up 2.5%. The filing reports no material off-balance-sheet arrangements.
Material changes and unusual items
- Net loss increased year over year, despite lower operating expenses, mainly because 2017 included a $512,104 loss associated with conversion of convertible notes and $127,425 of interest expense. The prior-year quarter included a $1.6 million acquired R&D impairment, a $149,728 patent-sale gain, fair-value gains on stock rights and warrants, and a $640,000 income-tax benefit.
- Sevion received $1.5 million from OPKO Health in July 2017 by issuing 10 million shares at $0.15 each. The financing triggered mandatory conversion of convertible notes: $750,000 principal plus accrued interest converted into 7,704,903 shares during the quarter. The remaining $250,000 principal and $4,290 accrued interest were expected to convert into 2,542,905 shares immediately before the proposed transaction closes.
- Common shares outstanding rose from 29,202,799 at June 30 to 51,414,613 at September 30, reflecting the OPKO issuance, note conversion, and preferred-stock exchanges. All Series A and Series C preferred shares were exchanged for common shares during the quarter.
- R&D spending was reduced to preserve cash; management cited lower headcount, reduced patent prosecution, lower facility rent after moving to a smaller site, and reduced research activity.
Liquidity, outlook, risks, and controls
Management estimated that September 30 cash would fund operations through December 31, 2017. It stated that failure to complete the Eloxx transaction or obtain additional financing could leave the company unable to continue as a going concern beyond that date. The filing expressly says these conditions raise substantial doubt about the company’s ability to continue as a going concern.
The proposed transaction was subject to closing conditions, including Eloxx stockholder approval and separate equity financings providing at least $12 million each to Sevion’s business and Eloxx. It was required to close by December 31, 2017, if it closed. Eloxx shareholders were to receive shares representing 71.60% of the combined company on the agreement’s specified fully diluted, as-converted basis, subject to adjustments. The filing does not provide a completed transaction outcome or definitive forward financial guidance.
Management identified continued operating losses, the need for additional capital, dilution, product-development and regulatory uncertainty, dependence on third parties, intellectual-property risks, and limited trading-market liquidity among material risks. If financing or the transaction failed, possible actions included licensing programs, seeking alliances or a sale, curtailing development, ceasing operations, or bankruptcy. Disclosure controls were reported ineffective because a material weakness in review and accounting for equity-linked instruments remained unremediated.
Important facts for investors to verify
- Whether the merger and both required equity financings closed by the stated deadline, and the final proceeds, share issuance, ownership split, and listing status.
- Cash runway and subsequent financing needs, given $957,874 cash, a $37,833 working-capital deficit, and management’s substantial-doubt disclosure.
- Final conversion and accounting treatment of the remaining convertible notes and related shares.
- Progress in remediating the internal-control material weakness and any resulting financial-statement adjustments.
- R&D program status and funding plans; the filing says research activity was sharply curtailed and gives no quantified commercialization outlook.